This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
Fleas are ectoparasitic blood-sucking insects with the ability to jump, which commonly infest wild and domestic animals (mainly dogs and cats) but also humans.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA.
Yellow fever (YF) is a mosquito-borne infection, distributed in west, central and east Africa and in South America. The disease can cause a wide spectrum of symptoms, from mild to fatal. In severe cases there may be spontaneous haemorrhage. Mortality of these clinical cases can be as high as 80%, on a par with Ebola, Marburg and other haemorrhagic viral infections.
This operational guidance document provides practical recommendations and key considerations to inform the development and
implementation of PrEP programmes at national and sub-national levels throughout the EU/EEA.
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.